Prolongation of rat islet allograft survival by the immunosuppressive agent Leflunomide

Transplantation

Volumn 63, Issue 5, 1997, Pages 711-716

  Guo, Zhiguang ^a   Chong, Anita S F ^a   Shen, Jikun ^a   Foster, Preston ^a   Sankary, Howard N ^a   McChesney, Lawrence ^a   Mital, Deepak ^a   Jensik, Stephen C ^a   Williams, James W ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MALE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; RAT; STRAIN DIFFERENCE; SURVIVAL TIME;

ANIMALS; EOSINE YELLOWISH-(YS); GRAFT SURVIVAL; HEMATOXYLIN; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; ISOXAZOLES; KIDNEY; MALE; RATS; RATS, INBRED LEW;

EID: 0030999181     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199703150-00017     Document Type: Article

References (25)

1. Inverardi L, Ricordi C, Transplantation of pancreas and islet of Langerhans: a review of progress. Immunol Today 1995; 17: 7.
2. Hahn HJ, Laube F, Lucke S, Kloting I, et al. Toxic effects of cyclosporine on the endocrine pancreas of Wistar rats. Transplantation 1986; 41: 44.
3. Hirano Y, Fujihira S, Ohara K, Katsuki S, Noguchi H. Morphological and functional changes of islets of Langerhans in FK506-treated rats. Transplantation 1992; 53: 889.
4. Jindal RM. Posttransplant diabetes mellitus: a review. Transplantation 1994; 58: 1289.
5. Bartlett RR, Schleyerbach R. Immunopharmacological profile of a novel isoxazole derivative HWA 486, with potential antirheumatic activity. I. Disease modifying action on adjuvant arthritis in the rat. Int J Immunopharmacol 1985; 7: 7.
6. Williams JW, Xiao F, Foster P, et al. Leflunomide in experimental transplantation; control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine. Transplantation 1994; 57: 1223.
7. Kuchle CC, Thoenes GH, Langer KH, Schorlemmer H-U, Barrlett RR, Schleyerbach R. Prevention of kidney and skin graft rejection in rats by lefluriomide, a new immunosuppressive isoxazole derivative. Transplant Proc 1991; 23: 1083.
8. D'Sliva M, Candinas D, Achilleos O, et al. The immunomodulatory effect of leflunomide in rat cardiac allotransplantation. Transplantation 1995; 60: 430.
9. McChesney LP, Xiao F, Sankary HN, et al. An evaluation of leflunomide in the canine renal transplantation model. Transplantation 1994; 57: 1717.
10. Morris RE, Huang X, Cao W, Zheng B, Shorthouse RA. Leflunomide (HWA 486) and its analog suppress T- and B-cell proliferation in vitro, acute rejection, ongoing rejection, and antidonor antibody synthesis in mouse, rat, and cynomolgus monkey transplant recipients as well as arterial intimal thickening after balloon catheter injury. Transplant Proc 1995; 27: 445.
11. Xiao F, Chong A, Foster P, et al. Leflunomide on acute rejection in hamster to rat cardiac xenografts. Transplantation 1995; 58: 828.
12. Wright JR Jr, Krarns H, MacDonald AS. Leflunomide and cyclosporin-A prolong fish-to-mouse islet xenograft survival in BALB/C mice. Transplant Proc 1994; 26: 1310.
13. Chong AS, Finnegan A, Jiang X, et al. Leflunomide, a novel immunosuppressive agent: the mechanism of inhibition of T cell proliferation. Transplantation 1993; 55: 1361.
14. Siemasko KF, Chong ASF, Williams JW, Bremer EG, Finnegan A. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 1996; 61: 635.
15. Xu X, Williams JW, Bremer EG, Finnegan A, Chong AS. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 1995; 270: 12398.
16. Mattar T, Kochhar K, Bartlett R, Bremer EG, Finnegan A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett 1993; 334: 161.
17. Greene S, Watanabe K, Braatz-Trulson J, Lou L. Inhibition of dihydroorate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 1995; 50: 861.
18. Williamson RA, Yea CM, Robson PA, et al. Dihydro-orotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J Biol Chem 1995; 270: 22467.
19. Lacy PE, Kostianovsky M. Method for isolation of islets of Langerhans from the rat pancreas. Diabetes 1967; 16: 35.
20. Scharp DW, Kemp CB, Knight MJ, Ballinger WF, Lacy PE. The use of Ficoll in preparation of viable islets of Langerhans from the rat pancreas. Transplantation 1973; 16: 686.
21. Dibelius A, Konigsberger H, Walter P, et al. Prolonged reversal of diabetes in the rat by transplantation of allogeneic islets from a single donor and cyclosporine treatment. Transplantation 1986; 41: 426.
22. Pipeleers-Marichal M, Ling Z-D, Teng H, Pipeleers DG. Transplantation of purified islet cells in diabetic rats. III. Immunosuppressive effect of cyclosporin. Diabetes 1991; 40: 931.
23. Ryu S, Yasunami Y. The necessity of differential immunosuppression for prevention of immune rejection by FK506 in rat islet allografts transplanted into the liver or beneath the kidney capsule. Transplantation 1991; 52: 599.
24. Tze WJ, Tai J, Cheung SSC, Murase N, Starzl TE. Successful islet allotransplantation in diabetic rats immunosuppressed with FK 506: a functional and immunological study. Metabolism 1994; 42: 135.
25. Guo Z, Chong ASF, Shen J, et al. In vivo effects of leflunomide on normal pancreatic islet and syngeneic islet graft function. Transplantation 1997; 63: 716.